I have often disagreed with Nathan A. Pennell MD, PhD, FASCO in Twitter debates, but for both of us, it is all in the spirit of vetting complex ideas. I know he is deeply committed to oncology & ASCO, including editing the ASCO educational book. I heartily endorse him for the Board of Directors.

Sent a patient home last week without evaluating a concern. Decided it didn't warrant evaluation. An hour later, while typing note, I had second thoughts. Called the pt and scheduled a test. Got the results today. Very glad I did the test. A close call.

What a DELIGHT to have her join us tonight for MD Anderson Cancer Center General Oncology Grand Rounds! @MissMeganEl @VUMCHemOnc

"Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis" @steliga UAMS Health UAMS Cancer This adds further evidence supporting the importance of smoking cessation after a cancer diagnosis. I hope to see more tobacco cessation specialists

Congratulations to the UAMS Health Hematology/Medical Oncology Fellowship Class of 2028! UAMS Cancer UAMS Internal Medicine Residency

⭐️One of the best-kept secrets in Nashville is Parnassus Books Parnassus Books , an incredible independent bookstore. I am so thankful for the invite to the holiday party at the bookstore with the next generation of future doctors & medicine residents from the amazing Dr. Karl

We report UAMS Myeloma Center the longest follow up of any myeloma phase III clinical trial Blood Advances ASH #mmsm Long Term Follow up of Total Therapy IV: A Phase III Clinical Trial for Standard Risk Multiple Myeloma ➡️ ashpublications.org/bloodadvances/… Median OS: 13.3 yrs 🧵

🔥🚨HOT OFF THE PRESS Just published Journal of Clinical Oncology IMPORTANT SPECIAL ARTICLE & #Recommendations for #Academic #MedicalCenters by ASCO on: Promoting Reasonable #CareerExpectations & Maximizing Professional Fulfillment for #Academic #Oncologists PLZ SHARE👇🏻 ascopubs.org/doi/10.1200/JC…

Calling on all Medical Oncologists to register for this crucial webinar on Feb 19 providing insights into reasons for ERRONEOUS Discontinuation of immunotherapy in pts with asymptomatic benign radiation fibrosis, and how to better evaluate post-tx chest CT scans.

🚨Calling all @asco #ASCO25 annual meeting attendees! Come join us in person for our annual #MedEd CoP event!! 🔔 Saturday May 31st 🔔 7:30-9:30 am 🔔 Room S103 ‼️Keynote speakers: TwoOncDocs and Oncology Brothers!! Can’t wait to see you there!! 🥰

#ASCO25 ASCO #ProTips for making the most of Annual Meeting 1⃣ Plan Ahead ✅Download App 🔖Bookmark sessions, talks Add to agenda! OncoAlert Hem-Onc Fellows Network Oncology Brothers The Fellow On Call

#ASCO25 ASCO #NSCLC #LCSM SWOG/NRG S1914 (Abstract 8003): Phase III trial in medically inoperable early-stage NSCLC: • 🛑 Adding atezolizumab to SBRT did not improve OS (HR 1.15, p=0.63) or PFS (HR 1.35, p=0.16) • ⏳ 2-year OS: 82% (SBRT alone) vs 80% (atezo+SBRT) • ⚠️ More

#ASCO25 ASCO #SCLC #LCSM IMforte (Abstract 8006): Phase 3 1L maintenance lurbinectedin + atezolizumab vs atezolizumab alone in extensive-stage SCLC: • ⏳ Median PFS: 5.4 vs 2.1 months (HR 0.54; p<0.0001) • 🕒 Median OS: 13.2 vs 10.6 months (HR 0.73; p=0.0174) • ⚠️ Grade

Check our long term follow up of earlier total therapy protocols in Arkansas JAMA Oncology UAMS Myeloma Center #mmsm ➡️ jamanetwork.com/journals/jamao… ✅ With time limited therapy&median follow up of ~17 years of 1202 patients, we estimate one out of three patients are cured from their multiple

It's amazing how far we've come in the ability to biopsy lung nodules compared to 15 years ago! Nikhil Meena Matthew Steliga MD FACS Sajjad Bhatti Sanjay Maraboyina MD

When Science Meets Home: Aligning Personal and Professional Life: Superheroes offer lesson in science, altruism and unnecessary capes ufhealth.org/news/2025/supe… Spyridoula Maraka Mike Mavros Samer Al Hadidi, MD,MS,FACP